Jill Lykon, Clinical Oncology Pharmacy Manager at the University of Miami Health System, posted on X/Twitter:
“To close out ASH23 we presented our data on toci pre-med prior to teclistamab step up dose 1. Low CRS (13%), no repeated doses of toci. Still need pharm-eco and response rate data to make this SOC.”
Source: Jill Lykon/X